{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:06:57Z","timestamp":1757311617389},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Research expenses from Toho University School of Medicine.","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10067-019-04473-w","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T13:54:30Z","timestamp":1550498070000},"page":"1571-1578","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus"],"prefix":"10.1007","volume":"38","author":[{"given":"Mai","family":"Kawazoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zento","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Masuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Shikano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kaburaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"4473_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gfw068","volume":"31","author":"CC Mok","year":"2016","unstructured":"Mok CC (2016) Con: cyclophosphamide for the treatment of lupus nephritis. Nephrol Dial Transplant 31:1053\u20131057","journal-title":"Nephrol Dial Transplant"},{"key":"4473_CR2","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1056\/NEJM199406303302608","volume":"330","author":"JA Mills","year":"1994","unstructured":"Mills JA (1994) Systemic lupus erythematosus. N Engl J Med 330:1871\u20131879","journal-title":"N Engl J Med"},{"key":"4473_CR3","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219\u20132228","journal-title":"N Engl J Med"},{"key":"4473_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D, the Aspreva Lupus Management Study Group (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103\u20131112","journal-title":"J Am Soc Nephrol"},{"key":"4473_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM, American College of Rheumatology (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64:797\u2013808","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4473_CR6","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, D\u00f6rner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven R, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT, European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771\u20131782","journal-title":"Ann Rheum Dis"},{"key":"4473_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/art.25052","volume":"62","author":"EM Ginzler","year":"2010","unstructured":"Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA, ALMS Group (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62:211\u2013221","journal-title":"Arthritis Rheum"},{"key":"4473_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3109\/s10165-009-0220-y","volume":"19","author":"Y Kusunoki","year":"2009","unstructured":"Kusunoki Y, Tanaka N, Kaneko K, Yamamoto T, Endo H, Kawai S (2009) Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. Mod Rheumatol 19:616\u2013621","journal-title":"Mod Rheumatol"},{"key":"4473_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00296-010-1366-9","volume":"31","author":"K Suzuki","year":"2011","unstructured":"Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Nishi E, Okuyama A, Tsuzaka K, Takeuchi T (2011) Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatol Int 31:757\u2013763","journal-title":"Rheumatol Int"},{"key":"4473_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/0961203315600538","volume":"25","author":"H Watanabe","year":"2016","unstructured":"Watanabe H, Yamanaka R, Sada KE, Zeggar S, Katsuyama E, Katsuyama T, Narazaki MT, Tatebe NT, Sugiyama K, Watanabe KS, Wakabayashi H, Kawabata T, Wada J, Makino H (2016) The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. Lupus 25:54\u201360","journal-title":"Lupus"},{"key":"4473_CR11","doi-asserted-by":"publisher","first-page":"686480","DOI":"10.1155\/2010\/686480","volume":"2010","author":"KH Yoon","year":"2010","unstructured":"Yoon KH (2010) Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol 2010:686480","journal-title":"J Biomed Biotechnol"},{"key":"4473_CR12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271\u20131277","journal-title":"Arthritis Rheum"},{"key":"4473_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","volume":"135","author":"GG Illei","year":"2001","unstructured":"Illei GG, Austin HA, Crane M, Collins L, Gourley MF et al (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248\u2013257","journal-title":"Ann Intern Med"},{"key":"4473_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992","journal-title":"Am J Kidney Dis"},{"key":"4473_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241\u2013250","journal-title":"J Am Soc Nephrol"},{"key":"4473_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630\u2013640","journal-title":"Arthritis Rheum"},{"key":"4473_CR17","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1177\/0961203311418269","volume":"20","author":"M Zeher","year":"2011","unstructured":"Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, Hiepe F, Prestele H, Bernhardt P, Amoura Z (2011) Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 20:1484\u20131493","journal-title":"Lupus"},{"key":"4473_CR18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1053\/j.ajkd.2012.11.042","volume":"61","author":"M Walsh","year":"2013","unstructured":"Walsh M, Solomons N, Lisk L, Jayne DR (2013) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 61:710\u2013715","journal-title":"Am J Kidney Dis"},{"key":"4473_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10157-010-0270-7","volume":"14","author":"EM El-Shafey","year":"2010","unstructured":"El-Shafey EM, Abdou SH, Shareef MM (2010) Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol 14:214\u2013221","journal-title":"Clin Exp Nephrol"},{"key":"4473_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/s10165-012-0634-9","volume":"23","author":"A Onishi","year":"2013","unstructured":"Onishi A, Sugiyama D, Tsuji G, Nakazawa T, Kogata Y, Tsuda K, Naka I, Nishimura K, Misaki K, Kurimoto C, Hayashi H, Kageyama G, Saegusa J, Sugimoto T, Kawano S, Kumagai S, Morinobu A (2013) Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study. Mod Rheumatol 23:89\u201396","journal-title":"Mod Rheumatol"},{"key":"4473_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/ard.62.6.534","volume":"62","author":"M Bijl","year":"2003","unstructured":"Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG (2003) Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 62:534\u2013539","journal-title":"Ann Rheum Dis"},{"key":"4473_CR22","first-page":"1508","volume":"30","author":"MM Riskalla","year":"2003","unstructured":"Riskalla MM, Somers EC, Fatica RA, McCune WJ (2003) Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 30:1508\u20131512","journal-title":"J Rheumatol"},{"key":"4473_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/0961203317739131","volume":"27","author":"N Kamanamool","year":"2018","unstructured":"Kamanamool N, Ingsathit A, Rattanasiri S, Ngamjanyaporn P, Kasitanont N, Chawanasuntorapoj R, Pichaiwong W, Anutrakulchai S, Sangthawan P, Ophascharoensuk V, Avihingsanon Y, Sumethkul V (2018) Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. Lupus 27:647\u2013656","journal-title":"Lupus"},{"key":"4473_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175152","volume":"12","author":"H Hanaoka","year":"2017","unstructured":"Hanaoka H, Kiyokawa T, Iida H, Ishimori K, Takakuwa Y, Okazaki T, Yamada H, Ichikawa D, Shirai S, Koike J, Ozaki S (2017) Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: a single-Centre retrospective study. PLoS One 12:e0175152","journal-title":"PLoS One"},{"key":"4473_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3109\/14397595.2015.1031444","volume":"25","author":"S Yasuda","year":"2015","unstructured":"Yasuda S, Atsumi T, Shimamura S, Ono K, Hiromura K, Sada K, Mori M, Takei S, Kawaguchi Y, Tamura N, Takasaki Y (2015) Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. Mod Rheumatol 25:854\u2013857","journal-title":"Mod Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04473-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04473-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04473-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T15:52:23Z","timestamp":1582041143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04473-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4473"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04473-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"19 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by the Ethics Committee at Toho University Omori Medical Center (approval no. M17140) and was conducted in accordance with the principles of the Declaration of Helsinki and its later amendments, and Ethical Guidelines for medical research targeting people by Ministry of Health, Labour and Welfare of the Japanese Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"HS received speaker fee from Chugai Pharmaceutical Co., Ltd. SM received speaker fee from Chugai Pharmaceutical Co., Ltd., and Pfizer Japan Inc. SK received research grants from Astellas Pharma Inc., Ayumi Pharmaceutical Co., and Chugai Pharmaceutical Co., Ltd. TN received grant\/research support from Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Pfizer Japan Inc., and Shionogi & Co., Ltd., consultant fees from Chugai Pharmaceutical Co., Ltd., and speaker fees from Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical Co., and Pfizer Japan Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}